PPLPHARMA.NS Balance Sheet
Piramal Pharma Ltd.
Profit & Loss Balance Sheet Cash Flow
Balance Sheet · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 23:43
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Property, Plant and Equipment | ₹33.63 Bn | ₹38.73 Bn | ₹41.76 Bn | ₹44.51 Bn | PropertyPlantAndEquipment |
| Capital Work-in-Progress | ₹8.53 Bn | ₹5.66 Bn | ₹4.89 Bn | ₹7.99 Bn | CapitalWorkInProgress |
| Goodwill | ₹11.08 Bn | ₹11.23 Bn | ₹11.48 Bn | ₹12.57 Bn | Goodwill |
| Other Intangible Assets | ₹27.73 Bn | ₹26.17 Bn | ₹24.51 Bn | ₹25.84 Bn | OtherIntangibleAssets |
| Non-current Investments | ₹0.42 Bn | ₹0.35 Bn | ₹0.44 Bn | ₹0.61 Bn | NoncurrentInvestments |
| Other Non-current Assets | ₹2.17 Bn | ₹4.72 Bn | ₹4.44 Bn | ₹5.22 Bn | OtherNoncurrentAssets |
| Total Non-current Assets | ₹96.87 Bn | ₹98.47 Bn | ₹98.81 Bn | ₹107.73 Bn | NoncurrentAssets |
| Inventories | ₹16.81 Bn | ₹21.76 Bn | ₹23.13 Bn | ₹30.64 Bn | Inventories |
| Trade Receivables | ₹17.99 Bn | ₹21.34 Bn | ₹23.50 Bn | ₹21.58 Bn | TradeReceivablesCurrent |
| Cash and Cash Equivalents | ₹1.96 Bn | ₹3.57 Bn | ₹3.69 Bn | ₹12.00 Bn | CashAndCashEquivalents |
| Current Investments | ₹4.27 Bn | ₹1.45 Bn | ₹0.20 Bn | ₹1.32 Bn | CurrentInvestments |
| Other Current Assets | ₹5.28 Bn | ₹5.11 Bn | ₹5.52 Bn | ₹5.49 Bn | OtherCurrentAssets |
| Total Current Assets | ₹48.35 Bn | ₹54.64 Bn | ₹57.97 Bn | ₹71.92 Bn | CurrentAssets |
| Total Assets | ₹145.23 Bn | ₹153.12 Bn | ₹156.78 Bn | ₹179.65 Bn | Assets |
| Equity Share Capital | ₹11.93 Bn | ₹13.23 Bn | ₹13.24 Bn | ₹13.27 Bn | EquityShareCapital |
| Other Equity | ₹55.80 Bn | ₹65.88 Bn | ₹68.01 Bn | ₹68.35 Bn | OtherEquity |
| Equity Attributable to Owners | ₹67.73 Bn | ₹79.11 Bn | ₹81.25 Bn | ₹81.63 Bn | EquityAttributableToOwnersOfParent |
| Non-controlling Interests | N/A | N/A | ₹0.00 Bn | ₹0.00 Bn | NonControllingInterest |
| Total Equity | ₹67.73 Bn | ₹79.11 Bn | ₹81.25 Bn | ₹81.63 Bn | Equity |
| Long-term Borrowings | ₹33.84 Bn | ₹24.84 Bn | ₹32.14 Bn | ₹43.00 Bn | BorrowingsNoncurrent |
| Total Non-current Liabilities | ₹39.06 Bn | ₹30.31 Bn | ₹37.86 Bn | ₹50.44 Bn | NoncurrentLiabilities |
| Short-term Borrowings | ₹21.21 Bn | ₹20.75 Bn | ₹15.06 Bn | ₹11.96 Bn | BorrowingsCurrent |
| Trade Payables | ₹11.93 Bn | ₹15.38 Bn | ₹15.34 Bn | ₹24.79 Bn | TradePayablesCurrent |
| Other Current Liabilities | ₹2.29 Bn | ₹3.87 Bn | ₹2.74 Bn | ₹5.93 Bn | OtherCurrentLiabilities |
| Total Current Liabilities | ₹38.43 Bn | ₹43.69 Bn | ₹37.66 Bn | ₹47.58 Bn | CurrentLiabilities |
| Total Equity and Liabilities | ₹145.23 Bn | ₹153.12 Bn | ₹156.78 Bn | ₹179.65 Bn | EquityAndLiabilities |
Every figure above is the exact value of the named XBRL element from PPLPHARMA.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).